BBA
CTNM

Baker Bros. Advisors’s Contineum Therapeutics CTNM Stock Holding History

Baker Bros. Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.6M Hold
1,420,838
– – 0.11% 55
2025
Q4 		$16.2M Buy
1,420,838
+1,343,168
+1,729% +$15.3M 0.1% 61
2025
Q3 		$913K Sell
77,670
-234,830
-75% -$1.89M 0.01% 85
2025
Q2 		$1.24M Hold
312,500
– – 0.01% 81
2025
Q1 		$2.18M Hold
312,500
– – 0.02% 75
2024
Q4 		$4.58M Hold
312,500
– – 0.05% 70
2024
Q3 		$5.98M Hold
312,500
– – 0.06% 62
2024
Q2 		$5.5M Buy
+312,500
New +$5.03M 0.07% 61

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baker Bros. Advisors's CTNM Position: Q1 2026 in Review

Baker Bros. Advisors held its Contineum Therapeutics (CTNM) position steady in Q1 2026 at 1,420,838 shares worth $18.6M. The position accounts for 0.11% of the portfolio, ranked #55.

Baker Bros. Advisors first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Baker Bros. Advisors held 1,420,838 shares of Contineum Therapeutics worth $18.6M as of Q1 2026.
  • Baker Bros. Advisors left its Contineum Therapeutics share count unchanged in Q1 2026.
  • Contineum Therapeutics made up 0.11% of Baker Bros. Advisors's portfolio in Q1 2026, its #55 holding.
  • Baker Bros. Advisors first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.